Blog Series: NIAID-DVI
Safety and immunogenicity of the NIH live attentuated tetravalent dengue vaccine candidate TV003
Stephen Whitehead
National Institutes of Allergy and Infectious Diseases, NIH
National Institutes of Allergy and Infectious Diseases, NIH
January 13, 2013, the NIH releases a news statement: NIH-developed candidate dengue vaccine shows promise in early-stage trial where they discuss the new vaccine for dengue that has done well in an early stage clinical trial, the study having been published in the Journal of Infectious disease 17 January 2013. Unfortunately the article is behind a paywall...curses!!! So I will do my best to convey what I can through other numerous links and information garnered from pillaged internet slides about the vaccine and of course what I learned in the meeting.
Falling back on John T. Roehrig's presentation because it's such a nice clear presentation...here is the make up TV003.
